The U.S. Food and Drug Administration approved Mirum Pharmaceuticals' genetic disorder drug on Friday, making it the first treatment for a rare condition that interferes with the body's ability to ...
In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 7,489 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42. ...
16:06 EST Mirum Pharmaceuticals (MIRM) sees FY25 product sales of $420M-$435M vs. $336.4M in FY24 See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze ...
Mirum Pharmaceuticals has a twelve month low of $23.14 and a twelve month high of $54.23. Several analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback